Study of Rubus Idaeus Juice Ellagitannins and Its Antimicrobial Activity
Ivan Polischuk,
Mykola Komisarenko,
Taras Upyr,
Alla Kovaleva,
Andriy Komisarenko
Issue:
Volume 5, Issue 6, November 2019
Pages:
68-71
Received:
11 October 2019
Accepted:
29 October 2019
Published:
13 November 2019
Abstract: Medicines on the basis of herbs are increasingly used for treating of many diseases, providing the following actions antimicrobial, antiviral, anticancer, anti-enzymatic and immunomodulatory. Ellagitannins are a group of polyphenolic compounds of plant origin, which exhibiting a strong antibacterial effect in virtue of their ability to form a bond with the microbial membrane. Raspberry contains a large amount of ellagitannins, so it is advisable to study their composition and content in raspberry juice, obtained in Ukraine and determine its antimicrobial activity. As raw material Ukrainian variety ‘Phenomenon’ was taken for the research. It was bred in 1991 in Kharkiv region by crossing the varieties ‘Stolichnaya’ and ‘Odarka’. Analysis of raspberry juice ellagitannins was performed by HPLC method. 4 ellagic acid derivatives were identified and their contents were established. Unbound ellagic acid (55% of all) and sanguiin H-6 (21% of all) had the highest content among them Antimicrobial activity of raspberry juice was studied by agar diffusion method. The juice showed antimicrobial activity against Staphylococcus aureus, Escherichia coli, Proteus vulgaris, Pseudomonas aeruginosa, Bacillus subtilis and Candida albicans. The antimicrobial activity of the juice was higher than the comparison drug " Chlorophyllipt " for more than twice in relation to all strains. The greatest effect was manifested relative to Staphylococcus aureus, which can be the cause of purulent-inflammatory processes in almost all human organs with severe consequences. This is especially true in connection with the increasing resistance of strains not only to traditional antibiotics, but also to new groups.
Abstract: Medicines on the basis of herbs are increasingly used for treating of many diseases, providing the following actions antimicrobial, antiviral, anticancer, anti-enzymatic and immunomodulatory. Ellagitannins are a group of polyphenolic compounds of plant origin, which exhibiting a strong antibacterial effect in virtue of their ability to form a bond ...
Show More
Duodenal Villous Atrophy and Diarrhea Associated with Chronic Olmesartan Intake
Giulia Colombo,
Raffaella Rossio,
Barbara Ferrari,
Letterio Runza,
Peyvandi Flora
Issue:
Volume 5, Issue 6, November 2019
Pages:
72-74
Received:
8 November 2019
Accepted:
29 November 2019
Published:
6 December 2019
Abstract: Olmesartan is an angiotensin II receptor blocker (ARB) approved for the treatment of hypertension since 2002. Olmesartan-associated enteropathy (OAE), first described in 2012 by Rubio-Tapia, has seldom been considered as a diagnosis in patients with villous atrophy and negative serology for celiac disease. The clinical presentation could be extremely heterogenous. In contrast to celiac disease, there is no response to a gluten-free diet. The exact mechanism of intestinal injury still remains unknown. The histological pattern, at the upper gastrointestinal endoscopy, usually reveals a variable degree of villous atrophy and a moderate infiltration of lymphocytes at mucosal level. Symptoms usually improve upon olmesartan discontinuation and the repeat endoscopy could demonstrate complete resolution of inflammatory change with normal villous architecture. The differential diagnosis for this kind of clinical and pathological features include celiac disease, tropical sprue, autoimmune enteropathy, inflammatory bowel disease, and drug induced enteropathy. With this background, we report the case of a patient with a clinical picture compatible with seronegative celiac disease and symptoms that rapidly improved clinically and histologically after olmesartan discontinuation. In conclusion, although this condition is rare, physicians should be consider this medication in the differential diagnosis of this enteropathy.
Abstract: Olmesartan is an angiotensin II receptor blocker (ARB) approved for the treatment of hypertension since 2002. Olmesartan-associated enteropathy (OAE), first described in 2012 by Rubio-Tapia, has seldom been considered as a diagnosis in patients with villous atrophy and negative serology for celiac disease. The clinical presentation could be extreme...
Show More
